33.44 - 34.57
31.40 - 61.90
7.61M / 5.95M (Avg.)
-152.73 | -0.22
Analyze analyst forecasts for the company and compare them with competitors.
1.24B
No peer data available for comparison.
-788.81M
No peer data available for comparison.
0.22
No peer data available for comparison.
118.22M
No peer data available for comparison.
-887.36M
No peer data available for comparison.
1.39B
No peer data available for comparison.
Analyze DCF forecasts for the company and compare them with competitors.
12.12B
Better than PATH's revenue of 7.67B.
66.85%
Better than PATH's revenue growth rate of 42.45%.
-7.73B
Worse than PATH's ebitda of -3.24B.
-63.74%
Worse than PATH's ebitda margin of -42.28%.
-8.69B
Worse than PATH's ebit of -3.40B.
-71.70%
Worse than PATH's ebit margin of -44.37%.
1.47B
Worse than PATH's depreciation of 232.25M.
11.11B
Better than PATH's total cash of 6.83B.
91.68%
Better than PATH's cash as percentage of revenue of 88.98%.
2.44B
Better than PATH's receivables of 2.91B.
20.14%
Better than PATH's receivables as percentage of revenue of 37.87%.
862.03M
Worse than PATH's inventories of 186.01M.
7.11%
Worse than PATH's inventories as percentage of revenue of 2.42%.
1.06B
Worse than PATH's accounts payable of 74.65M.
8.77%
Worse than PATH's payables as percentage of revenue of 0.97%.
-1.18B
Better than PATH's capital expenditure of -169.45M.
-9.73%
Better than PATH's capex as percentage of revenue of -2.21%.
11.55%
Worse than PATH's weighted average cost of capital (wacc) of 8.47%.
11.58%
Worse than PATH's cost of equity of 8.51%.
4.40%
Equal to PATH's cost of debt of 4.40%.
1.52
Worse than PATH's beta of 0.87.
534.88M
Better than PATH's diluted shares outstanding of 563.86M.
99.49M
Worse than PATH's total debt of 67.07M.
23.34B
Better than PATH's total equity of 7.31B.
23.44B
Better than PATH's total capital of 7.38B.
0.42%
Better than PATH's debt weighting of 0.91%.
99.58%
Better than PATH's equity weighting of 99.09%.
-8.69B
Worse than PATH's ebiat of -3.39B.
-9.30B
Worse than PATH's unlevered free cash flow of -4.22B.
2.00%
Equal to PATH's long-term growth rate of 2.00%.
-99.35B
Worse than PATH's terminal value of -66.62B.
-71.64B
Worse than PATH's enterprise value of -53.14B.
-36.05M
Worse than PATH's net debt of -994.61M.
-71.60B
Worse than PATH's equity value of -52.14B.
-133.86
Worse than PATH's equity value per share of -92.48.
View analysts' price targets and recommendations, and compare them with competitors.
$49.00
Analysts expect the stock price to increase by 45.83%.
Buy
Positive consensus among analysts.
